Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 1 Lack of normalisation of any liver enzyme reported in the study.
Figuras y tablas -
Analysis 1.1

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 1 Lack of normalisation of any liver enzyme reported in the study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 2 Lack of normalisation of all liver enzymes reported in the study.
Figuras y tablas -
Analysis 1.2

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 2 Lack of normalisation of all liver enzymes reported in the study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 3 Lack of normalisation of 5' nucleotidase.
Figuras y tablas -
Analysis 1.3

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 3 Lack of normalisation of 5' nucleotidase.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 4 Lack of normalisation of aspartate transaminase.
Figuras y tablas -
Analysis 1.4

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 4 Lack of normalisation of aspartate transaminase.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 5 Lack of normalisation of alanine transferase.
Figuras y tablas -
Analysis 1.5

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 5 Lack of normalisation of alanine transferase.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 6 Lack of normalisation of gammaglutamate transferase.
Figuras y tablas -
Analysis 1.6

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 6 Lack of normalisation of gammaglutamate transferase.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 7 Need for liver transplantation.
Figuras y tablas -
Analysis 1.7

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 7 Need for liver transplantation.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 8 Death related to liver disease.
Figuras y tablas -
Analysis 1.8

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 8 Death related to liver disease.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 9 Death due to all causes.
Figuras y tablas -
Analysis 1.9

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 9 Death due to all causes.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 10 Change in weight (kg).
Figuras y tablas -
Analysis 1.10

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 10 Change in weight (kg).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 11 Development of portal hypertension.
Figuras y tablas -
Analysis 1.11

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 11 Development of portal hypertension.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 12 Development of complications of portal hypertension.
Figuras y tablas -
Analysis 1.12

Comparison 1 UDCA versus placebo/no additional treatment (all groups given 'conventional care'), Outcome 12 Development of complications of portal hypertension.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. UDCA versus placebo/no additional treatment (all groups given 'conventional care')

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Lack of normalisation of any liver enzyme reported in the study Show forest plot

2

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 6 months

2

16

Odds Ratio (M‐H, Fixed, 95% CI)

0.09 [0.01, 1.24]

2 Lack of normalisation of all liver enzymes reported in the study Show forest plot

2

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 6 months

2

16

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Lack of normalisation of 5' nucleotidase Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

3.1 6 months

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Lack of normalisation of aspartate transaminase Show forest plot

2

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 6 months

2

14

Odds Ratio (M‐H, Fixed, 95% CI)

11.0 [0.43, 284.30]

5 Lack of normalisation of alanine transferase Show forest plot

2

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 6 months

2

12

Odds Ratio (M‐H, Fixed, 95% CI)

0.41 [0.04, 4.01]

6 Lack of normalisation of gammaglutamate transferase Show forest plot

2

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 6 months

2

10

Odds Ratio (M‐H, Fixed, 95% CI)

0.33 [0.02, 6.65]

7 Need for liver transplantation Show forest plot

3

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 0 to 6 months

2

30

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.2 7 to 12 months

1

28

Odds Ratio (M‐H, Fixed, 95% CI)

2.79 [0.10, 74.63]

8 Death related to liver disease Show forest plot

2

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 0 to 6 months

2

30

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.2 7 to 12 months

0

0

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

9 Death due to all causes Show forest plot

2

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 0 to 6 months

2

30

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.2 7 to 12 months

0

0

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

10 Change in weight (kg) Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

10.1 0 to 6 months

2

30

Mean Difference (IV, Fixed, 95% CI)

‐0.90 [‐1.94, 0.14]

11 Development of portal hypertension Show forest plot

2

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 0 to 6 months

2

30

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.2 7 to 12 months

0

0

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

12 Development of complications of portal hypertension Show forest plot

2

Odds Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 0 to 6 months

2

30

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

12.2 7 to 12 months

0

0

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 1. UDCA versus placebo/no additional treatment (all groups given 'conventional care')
Ir a la tabla de la revisión